ÂÜÀòÂÒÂ×

Tom Lillie is a seasoned medical executive currently serving as Chief Medical Officer at Grey Wolf Therapeutics since May 2023 and at Akamis Bio since January 2020. Lillie held significant roles in MSD as Vice President, overseeing both Oncology Global Medical Affairs and European Clinical Development from February 2016 to December 2019. Prior to this, Lillie contributed to Amgen from August 2002 to January 2016 in various capacities, including Therapeutic Area Head for Oncology and Global Development leader for Aranesp. Lillie's career began at Aventis as a Medical Affairs Manager from 2000 to 2003. Academically, Lillie earned a BA (hons) in Medicine from the University of Oxford and further advanced education with an MD and a PhD in Cell Biology from UCL.